Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 5/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8069350 | 1.00 | SLC5A1 (0.44) | SLC5A1SLC5A2POLBMAPTALDH1A1 | |
| SCHEMBL8067119 | 0.98 | SLC5A1 (0.43) | SLC5A1SLC5A2POLBMAPTALDH1A1 | |
| SCHEMBL5515342 | 0.95 | SLC5A1 (0.45) | SLC5A1SLC5A2POLBMAPTALDH1A1 | |
| SCHEMBL7828627 | 0.91 | SLC5A1 (0.44) | SLC5A1SLC5A2POLBMAPTALDH1A1 | |
| SCHEMBL27367023 | 0.89 | POLB (0.41) | POLBMAPTALDH1A1HSD17B10KDM4E | |
| SCHEMBL7827659 | 0.88 | SLC5A1 (0.43) | SLC5A1SLC5A2POLBMAPTALDH1A1 | |
| SCHEMBL8067099 | 0.88 | UCHL1 (0.38) | SLC5A1SLC5A2POLBMAPTALDH1A1 | |
| SCHEMBL5509234 | 0.88 | UCHL1 (0.38) | SLC5A1SLC5A2POLBMAPTALDH1A1 | |
| SCHEMBL8071411 | 0.86 | UCHL1 (0.39) | SLC5A1SLC5A2POLBMAPTALDH1A1 | |
| SCHEMBL7826196 | 0.86 | SLC5A1 (0.43) | SLC5A1SLC5A2POLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238812-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEJI SEIKA KAISHA, LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| US-7022860-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1026167-B1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS | MEIJI SEIKA KAISHA (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-20020137739-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| US-6372735-B1 | ANTIHISTAMINES | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-1026167-A1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC | MEIJI SEIKA KAISHA LTD. (JP) | 2000-08-09 | — | — | EP | disclosed |
| US-6093714-A | AN ANTIALLERGENS FOR TREATMENT AND PREVENTION OF BRONCHIAL ASTHMA, ECZEMA, HIVES, ALLERGIC GASTROINTESTINAL TROUBLES, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS | MEIJI SEIKA KAISHA, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-0834512-A1 | TRICYCLIC BENZAZEPINE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1998-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | HRH4, CYP2D6, CYP2B6 | SLC5A1 1786/4885SLC5A2 2190/4885POLB 2970/4885 |
| US-20020137739-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | HRH4, CYP3A4, TPH1 | SLC5A1 1282/4885SLC5A2 1586/4885POLB 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.